Jazz Pharmaceuticals (JAZZ) receives coverage from Piper Jaffray with an initial rating of...

|About: Jazz Pharmaceuticals, Inc. (JAZZ)|By:, SA News Editor

Jazz Pharmaceuticals (JAZZ) receives coverage from Piper Jaffray with an initial rating of Overweight and a $51 price target. Shares +1.4% premarket.